The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Single-dose infusion ketamine and non-ketamine N -methyl- d -aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories
Open accessAbstract
Background: Ketamine and non-ketamine N -methyl- d -aspartate receptor antagonists (NMDAR antagonists) recently demonstrated antidepressant efficacy for the treatment of refractory depression, but effect sizes, trajectories and possible class effects are unclear. Method: We searched PubMed/PsycINFO/Web of Science/clinicaltrials.gov until 25 August 2015. Parallel-group or cross-over randomized controlled trials (RCTs) comparing single intravenous infusion of ketamine or a non-ketamine NMDAR antagonist v. placebo/pseudo-placebo in patients with major depressive disorder (MDD) and/or bipolar depression (BD) were included in the analyses. Hedges’ g and risk ratios and their 95% confidence intervals (CIs) were calculated using a random-effects model. The primary outcome was depressive symptom change. Secondary outcomes included response, remission, all-cause discontinuation and adverse effects. Results: A total of 14 RCTs (nine ketamine studies: n = 234; five non-ketamine NMDAR antagonist studies: n = 354; MDD = 554, BD = 34), lasting 10.0 ± 8.8 days, were meta-analysed. Ketamine reduced depression significantly more than placebo/pseudo-placebo beginning at 40 min, peaking at day 1 (Hedges' g = −1.00, 95% CI −1.28 to −0.73, p < 0.001), and loosing superiority by days 10–12. Non-ketamine NMDAR antagonists were superior to placebo only on days 5–8 (Hedges' g = −0.37, 95% CI −0.66 to −0.09, p = 0.01). Compared with placebo/pseudo-placebo, ketamine led to significantly greater response (40 min to day 7) and remission (80 min to days 3–5). Non-ketamine NMDAR antagonists achieved greater response at day 2 and days 3–5. All-cause discontinuation was similar between ketamine ( p = 0.34) or non-ketamine NMDAR antagonists ( p = 0.94) and placebo. Although some adverse effects were more common with ketamine/NMDAR antagonists than placebo, these were transient and clinically insignificant. Conclusions: A single infusion of ketamine, but less so of non-ketamine NMDAR antagonists, has ultra-rapid efficacy for MDD and BD, lasting for up to 1 week. Development of easy-to-administer, repeatedly given NMDAR antagonists without risk of brain toxicity is of critical importance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The peak antidepressant effect of ketamine is seen 24 hours post administration, with sustained effects lasting 1-2 weeks 43 .”
From Imaging the effect of ketamine on synaptic density (SV2A) in the living brain (2022) · cites this paper as [43]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The antidepressant effects of an acute dose of ketamine are typically thought to occur within hours, peak around 24 h then gradually decline over a period of 10-12 days [10].”
From Ketamine in neuropsychiatric disorders: an update (2024) · cites this paper as [10]
The cited source says what the claim attributes to it.
In the citing paper
“Ketamine's antidepressant effects peak 1 day following infusion and typically dissipate 1-2 weeks after a single infusion (Kishimoto et al, 2016).”
From Ketamine for Social Anxiety Disorder: A Randomized, Placebo-Controlled Crossover Trial (2018) · cites this paper as Kishimoto et al, 2016
In the citing paper
“Multiple meta-analyses55–59 have now concluded that intravenous ketamine is effective as a rapid-acting antidepressant for major depressive episodes in both unipolar and bipolar depression”
From Ketamine as an antidepressant: Overview of its mechanisms of action and potential predictive biomarkers (2020) · cites this paper as [55]
In the citing paper
“While several of these studies have supported claims that ketamine’s antidepressant effect lasts up to 7 days,55,56 other authors have suggested this to be true only for unipolar depression.”
From Ketamine as an antidepressant: Overview of its mechanisms of action and potential predictive biomarkers (2020) · cites this paper as [55]
In the citing paper
“Furthermore, a meta-analysis of single-infusion non-ketamine NMDA receptor antagonists, including traxoprodil, lanicemine and rapastinel (GLYX-13), showed smaller effect sizes in depressive symptom change in comparison with ketamine and non-superiority in remission compared with placebo for unipolar and bipolar depression.55”
From Ketamine as an antidepressant: Overview of its mechanisms of action and potential predictive biomarkers (2020) · cites this paper as [55]
In the citing paper
“A major meta-analysis indicated no difference between ketamine and placebo groups on patient reports of ‘tired/fatigued’ and ‘vivid dreams’.55”
From Ketamine as an antidepressant: Overview of its mechanisms of action and potential predictive biomarkers (2020) · cites this paper as [55]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Larkin, G. L., & Beautrais, A. L. (2011) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711000629 · Cited by 259
RetractedThe Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Higgins, J. P. T., Altman, D. G., Gotzsche, P. C., Juni, P., Moher, D., Oxman, A. D., Savovic, J., Schulz, K. F., Weeks, L., Sterne, J. A. C., et al. (2011) · BMJ · doi:10.1136/bmj.d5928 · Cited by 33,817
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817
Dermyshi, E., Wang, Y., Yan, C., Hong, W., Qiu, G., Gong, X., & Zhang, T. (2017) · Neonatology · doi:10.1159/000454668 · Cited by 24,586
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
The Brief Psychiatric Rating Scale.
Overall, J. E., & Gorham, D. R. (1962) · Psychological Reports · doi:10.2466/pr0.1962.10.3.799 · Cited by 11,090
Murray, C. J. L., Vos, T., Lozano, R., Naghavi, M., Flaxman, A. D., Michaud, C., Ezzati, M., Shibuya, K., Salomon, J. A., Abdalla, S., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61689-4 · Cited by 8,888
A Rating Scale for Mania: Reliability, Validity and Sensitivity
Young, R. C., Biggs, J. T., Ziegler, V. E., & Meyer, D. A. (1978) · British Journal of Psychiatry · doi:10.1192/bjp.133.5.429 · Cited by 8,744
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,526
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643
Research works printed but not linked: 1
- Higgins, 2011, Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0
Cited by
Sorted by citations
Items 101–200 of 359
Zheng, W., Zhou, Y., Liu, W.-J., Wang, C., Zhan, Y., Li, H.-Q., Chen, L., Li, M. D., & Ning, Y. (2019) · Journal of Psychopharmacology · doi:10.1177/0269881119827811 · Cited by 56
Fujita, A., Fujita, Y., Pu, Y., Chang, L., & Hashimoto, K. (2019) · Psychopharmacology · doi:10.1007/s00213-019-05346-5 · Cited by 53
Draganov, M., Vives‐Gilabert, Y., de Diego-Adeliño, J., Vicent-Gil, M., Puigdemont, D., & Portella, M. J. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.01.138 · Cited by 53
Ma, L., Zhang, J., Fujita, Y., Qu, Y., Shan, J., Wan, X., Wang, X., Ishima, T., Kobayashi, K., Wang, L., et al. (2022) · Translational Psychiatry · doi:10.1038/s41398-022-01803-6 · Cited by 52
Li, D.-J., Wang, F.-C., Chu, C.-S., Chen, T.-Y., Tang, C.-H., Yang, W.-C., Chow, P. C.-K., Wu, C.-K., Tseng, P.-T., & Lin, P.-Y. (2017) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2016.11.008 · Cited by 51
Differential regulation of GluA1 expression by ketamine and memantine
Zhang, K., Yamaki, V. N., Wei, Z., Zheng, Y., & Cai, X. (2017) · Behavioural Brain Research · doi:10.1016/j.bbr.2016.09.002 · Cited by 51
Vidal, S. I., Gex‐Fabry, M., Bancila, V., Michalopoulos, G., Warrot, D., Jermann, F., Dayer, A. G., Virginie Sterpenich, A., Schwartz, S., Vutskits, L., et al. (2018) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000960 · Cited by 51
Lack of metabolism in (R)-ketamine’s antidepressant actions in a chronic social defeat stress model
Zhang, K., Fujita, Y., & Hashimoto, K. (2018) · Scientific Reports · doi:10.1038/s41598-018-22449-9 · Cited by 50
Zhang, K., Dong, C., Fujita, Y., Fujita, A., & Hashimoto, K. (2017) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyx100 · Cited by 50
Xiong, Z., Fujita, Y., Zhang, K., Pu, Y., Chang, L., Ma, M., Chen, J., & Hashimoto, K. (2019) · Behavioural Brain Research · doi:10.1016/j.bbr.2019.111904 · Cited by 49
Zhou, Y., Wu, F., Liu, W.-J., Zheng, W., Wang, C., Zhan, Y., Lan, X., & Ning, Y. (2020) · Translational Psychiatry · doi:10.1038/s41398-020-00945-9 · Cited by 49
Huang, C., Wu, Z., Wang, D., Qu, Y., Zhang, J., Jiang, R., Xu, X., Xu, X., Wang, Y., Liu, H., et al. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02288-5 · Cited by 49
BDNF as a Mediator of Antidepressant Response: Recent Advances and Lifestyle Interactions
Cubillos, S., Engmann, O., & Brancato, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232214445 · Cited by 47
Pharmacological Treatment of Bipolar Depression: What are the Current and Emerging Options?
Yalın, N., & Young, A. H. (2020) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s245166 · Cited by 48
Kohtala, S., Alitalo, O., Rosenholm, M., Rozov, S. V., & Rantamäki, T. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107741 · Cited by 47
Veraart, J. K. E., Smith-Apeldoorn, S. Y., Bakker, I. M., Visser, B. A. E., Kamphuis, J., Schoevers, R. A., & Touw, D. J. (2021) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyab039 · Cited by 49
Chronic Pain and Chronic Opioid Use After Intensive Care Discharge – Is It Time to Change Practice?
Stamenković, D., Laycock, H. C., Καρανικόλας, Μ., Ladjevic, N. G., Nešković, V., & Bantel, C. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00023 · Cited by 45
Zhou, Y., Peng, Y., Sun, W., Wang, J., Zhang, G., Zhen, L., Ren, X., Wang, A., Lin, S., Chan, M. T. V., et al. (2021) · Anesthesia & Analgesia · doi:10.1213/ane.0000000000005752 · Cited by 44
Smith-Apeldoorn, S. Y., Veraart, J. K. E., Kamphuis, J., van Asselt, A. D. I., Touw, D. J., Rot, M. A. H., & Schoevers, R. A. (2019) · BMC Psychiatry · doi:10.1186/s12888-019-2359-1 · Cited by 44
Ketamine in Major Depressive Disorder: Mechanisms and Future Perspectives
Shin, C., & Kim, Y. (2020) · Psychiatry Investigation · doi:10.30773/pi.2019.0236 · Cited by 47
A meta-analysis of the effects of ketamine on suicidal ideation in depression patients
Shen, Z., Gao, D., Lv, X., Wang, H., & Yue, W. (2024) · Translational Psychiatry · doi:10.1038/s41398-024-02973-1 · Cited by 41
Jelen, L. A., Lythgoe, D. J., Stone, J. M., Young, A. H., & Mehta, M. A. (2025) · Nature Medicine · doi:10.1038/s41591-025-03800-w · Cited by 41
Ketamine for Treatment of Mood Disorders and Suicidality: A Narrative Review of Recent Progress
Kritzer, M. D., Mischel, N., Young, J. R., Lai, C. S., Masand, P. S., Szabo, S. T., & Mathew, S. J. (2021) · Annals of Clinical Psychiatry · doi:10.12788/acp.0048 · Cited by 43
Real‐world effectiveness of repeated ketamine infusions for treatment‐resistant bipolar depression
Fancy, F., Rodrigues, N. B., Di Vincenzo, J. D., Chau, E. H., Sethi, R., Husain, M. I., Gill, H., Tabassum, A., Mckenzie, A., Phan, L., et al. (2023) · Bipolar Disorders · doi:10.1111/bdi.13284 · Cited by 40
Conley, A. A., Norwood, A. E. Q., Hatvany, T. C., Griffith, J. D., & Barber, K. E. (2021) · Psychopharmacology · doi:10.1007/s00213-021-05825-8 · Cited by 39
Backing into the future: pharmacological approaches to the management of resistant depression
Cowen, P. J. (2017) · Psychological Medicine · doi:10.1017/s003329171700068x · Cited by 39
A predictive coding framework for understanding major depression
Gilbert, J. R., Wusinich, C., & Zarate, C. A. (2022) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2022.787495 · Cited by 38
Self-citationHashimoto, K., Zhao, M., Zhu, T., Wang, X., & Yang, J. (2024) · Journal of Anesthesia and Translational Medicine · doi:10.1016/j.jatmed.2024.07.001 · Cited by 38
Ketamine and Electroconvulsive Therapy for Treatment-Refractory Depression
Huang, X., & Zheng, W. (2023) · ALPHA PSYCHIATRY · doi:10.5152/alphapsychiatry.2023.231358 · Cited by 38
Park, L., Furey, M., Nugent, A. C., Farmer, C., Ellis, J., Szczepanik, J. E., Lener, M. S., & Zarate, C. A. (2018) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyy051 · Cited by 37
Self-citationRobison, R., Lafrance, A., Brendle, M., Smith, M., Moore, C., Ahuja, S., Richards, S., Hawkins, N., & Strahan, E. (2022) · Journal of Eating Disorders · doi:10.1186/s40337-022-00588-9 · Cited by 36
de la Salle, S., Phillips, J. L., Blier, P., & Knott, V. (2021) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2021.110507 · Cited by 37
Ketamine as a Novel Psychopharmacotherapy for Eating Disorders: Evidence and Future Directions
Ragnhildstveit, A., Slayton, M., Jackson, L. K., Brendle, M., Ahuja, S., Holle, W., Moore, C., Sollars, K., Seli, P., & Robison, R. (2022) · Brain Sciences · doi:10.3390/brainsci12030382 · Cited by 35
Rodolico, A., Cutrufelli, P., Francesco, A. D., Aguglia, A., Catania, G., Concerto, C., Cuomo, A., Fagiolini, A. M., Lanza, G., Mineo, L., et al. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1325399 · Cited by 40
Veraart, J. K. E., Smith-Apeldoorn, S. Y., Spaans, H., Kamphuis, J., & Schoevers, R. A. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.11.123 · Cited by 35
Ketamine in Bipolar Disorder: A Review
Wilkowska, A., Szałach, Ł. P., & Cubała, W. J. (2020) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s282208 · Cited by 35
O’Brien, B., Lijffijt, M., Wells, A., Swann, A. C., & Mathew, S. J. (2019) · Pharmaceuticals · doi:10.3390/ph12030133 · Cited by 33
Sex dependence of opioid-mediated responses to subanesthetic ketamine in rats
Ianni, T. D., Ewbank, S. N., Levinstein, M. R., Azadian, M. M., Budinich, R. C., Michaelides, M., & Airan, R. D. (2024) · Nature Communications · doi:10.1038/s41467-024-45157-7 · Cited by 33
Maintenance Ketamine Therapy for Treatment-Resistant Depression
Archer, S., Chrenek, C., & Swainson, J. (2018) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000894 · Cited by 33
What is bipolar disorder? A disease model of dysregulated energy expenditure
Mansur, R. B., Lee, Y. L., McIntyre, R. S., & Brietzke, E. M. (2020) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2020.04.006 · Cited by 33
Ketamine improves short-term plasticity in depression by enhancing sensitivity to prediction errors
Sumner, R. L., McMillan, R., Spriggs, M. J., Campbell, D., Malpas, G., Maxwell, E., Deng, C., Hay, J., Ponton, R., Sundram, F., et al. (2020) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2020.07.009 · Cited by 32
Zhang, K., Toki, H., Fujita, Y., Ma, M., Chang, L., Qu, Y., Harada, S., Nemoto, T., Mizuno‐Yasuhira, A., Yamaguchi, J., et al. (2018) · Psychopharmacology · doi:10.1007/s00213-018-5017-2 · Cited by 32
Veraart, J. K. E., van Westenbrugge, M., Palthe, J. E. V. W., van der Meij, A., Schoevers, R. A., & de Jong, J. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e15883 · Cited by 31
Guo, H., Wang, B., Yuan, S., Wu, S., Liu, J., He, M., & Wang, J. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.849758 · Cited by 32
Ketamine-assisted psychotherapy in adolescents with multiple psychiatric diagnoses
Wolfson, P. E., Andries, J., Ahlers, D., & Whippo, M. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1141988 · Cited by 31
Emerging evidence for antidepressant actions of anesthetic agents
Tadler, S. C., & Mickey, B. J. (2018) · Current Opinion in Anaesthesiology · doi:10.1097/aco.0000000000000617 · Cited by 32
Wei, Y., Chang, L., & Hashimoto, K. (2021) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2021.04.010 · Cited by 30
The effects of ketamine on typical and atypical depressive symptoms
Park, L. T., Luckenbaugh, D. A., Pennybaker, S. J., Hopkins, M., Henter, I. D., Lener, M. S., Kadriu, B., Ballard, E. D., & Zarate, C. A. (2020) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13216 · Cited by 30
Self-citationZhang, K., Ma, M., Dong, C., & Hashimoto, K. (2018) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyy065 · Cited by 30
Ketamine for bipolar depression: an updated systematic review
Fancy, F., Haikazian, S., Johnson, D. E., Chen-Li, D. C. J., Levinta, A., Husain, M. I., Mansur, R. B., & Rosenblat, J. D. (2023) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253231202723 · Cited by 29
Okada, M., Fukuyama, K., Nakano, T., & Ueda, Y. (2019) · Biomolecules · doi:10.3390/biom9110746 · Cited by 29
Griffiths, C., Walker, K., Reid, I., da Silva, K. M., & O’Neill-Kerr, A. (2021) · Journal of Affective Disorders Reports · doi:10.1016/j.jadr.2021.100079 · Cited by 32
Larrea, A., Sánchez-Sánchez, L., Díez-Martín, E., Elexpe, A., Torrecilla, M., Astigarraga, E., & Barreda‐Gómez, G. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13061727 · Cited by 28
Lijffijt, M., Murphy, N., Iqbal, S., Green, C. E., Iqbal, T., Chang, L. C., Haile, C. N., Hirsch, L. C., Ramakrishnan, N., Fall, D. A., et al. (2021) · Neuropsychopharmacology · doi:10.1038/s41386-021-01242-9 · Cited by 31
Trends in research on novel antidepressant treatments
Zelek-Molik, A., & Litwa, E. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1544795 · Cited by 27
Registered clinical trials investigating ketamine for psychiatric disorders
Peyrovian, B., McIntyre, R. S., Phan, L., Lui, L. M. W., Gill, H., Majeed, A., Chen-Li, D. C. J., Nasri, F., & Rosenblat, J. D. (2020) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2020.03.020 · Cited by 27
Ketamine treatment for depression: qualitative study exploring patient views
Jilka, S., Odoi, C. M., Wilson, E., Meran, S., Simblett, S. K., & Wykes, T. (2021) · BJPsych Open · doi:10.1192/bjo.2020.165 · Cited by 28
Le, T. T., Vincenzo, J. D. D., Teopiz, K. M., Lee, Y. L., Cha, D. S., Lui, L. M. W., Rodrigues, N. B., Ho, R., Cao, B., Lin, K., et al. (2021) · Psychiatry Research · doi:10.1016/j.psychres.2021.114231 · Cited by 27
Fujita, Y., Hashimoto, Y., Hashimoto, H., Chang, L., & Hashimoto, K. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.173954 · Cited by 26
Forman‐Hoffman, V. L., Nelson, B. W., Ranta, K., Nazander, A., Hilgert, O., & Quevedo, J. (2021) · Internet Interventions · doi:10.1016/j.invent.2021.100408 · Cited by 27
Deletion of serine racemase confers D-serine –dependent resilience to chronic social defeat stress
Dong, C., Zhang, J., Ren, Q., Ma, M., Qu, Y., Zhang, K., Yao, W., Ishima, T., Mori, H., & Hashimoto, K. (2018) · Neurochemistry International · doi:10.1016/j.neuint.2018.03.008 · Cited by 26
Zhu, X., Zhang, F., You, Y., Wang, H., Yuan, S., Wu, B., Zhu, R., Liu, D., Yan, F., & Wang, Z. (2022) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-021-01180-6 · Cited by 26
Murphy, N., Tamman, A. J. F., Lijffijt, M., Amarneh, D. Y., Iqbal, S., Swann, A. C., Averill, L. A., O’Brien, B., & Mathew, S. J. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-023-01586-4 · Cited by 24
Glutamatergic augmentation strategies in obsessive–compulsive disorder
Narayanaswamy, J., & Sheshachala, K. (2019) · Indian Journal of Psychiatry · doi:10.4103/psychiatry.indianjpsychiatry_520_18 · Cited by 24
Phillips, J. L., Jaworska, N., Kamler, E., Bhat, V., Blier, J., Foster, J. A., Hassel, S., Ho, K. T., McMurray, L., Milev, R. V., et al. (2020) · BMC Psychiatry · doi:10.1186/s12888-020-02672-3 · Cited by 24
Nonopioid Analgesics for the Perioperative Geriatric Patient: A Narrative Review
Wilson, S. H., Wilson, P. R., Bridges, K. H., Bell, L. H., & Clark, C. A. (2022) · Anesthesia & Analgesia · doi:10.1213/ane.0000000000005944 · Cited by 23
Niciu, M. J., Iadarola, N. D., Banerjee, D., Luckenbaugh, D. A., Park, M., Lener, M. S., Park, L., Ionescu, D. F., Ballard, E. D., Brutsché, N. E., et al. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881117732514 · Cited by 23
Self-citationKetamine in the Treatment of Depressive Episodes
Ritter, P. S., Findeis, H., & Bauer, M. (2019) · Pharmacopsychiatry · doi:10.1055/a-0991-0582 · Cited by 26
Self-citationLipsitz, O., McIntyre, R. S., Rodrigues, N. B., Kaster, T. S., Cha, D. S., Brietzke, E. M., Gill, H., Nasri, F., Lin, K., Subramaniapillai, M., et al. (2020) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2020.110126 · Cited by 23
The future of psychiatry: clinical practice, diagnosis, and treatment
Turner, S., Yadav, P., Morrin, H., & Bhat, A. (2025) · International Review of Psychiatry · doi:10.1080/09540261.2025.2594523 · Cited by 23
Huang, X., Huang, X., He, H., Mei, F., Sun, B., Zhou, S., Yan, S., Zheng, W., & Ning, Y. (2020) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s248190 · Cited by 21
Increased use of ketamine for the treatment of depression: Benefits and concerns
Na, K., & Kim, Y. (2020) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2020.110060 · Cited by 23
New investigational agents for the treatment of major depressive disorder
Pochwat, B., Krupa, A. J., Siwek, M., & Szewczyk, B. (2022) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2022.2113376 · Cited by 22
Transcranial magnetic stimulation and ketamine: implications for combined treatment in depression
Dębowska, W., Więdłocha, M., Dębowska, M. D., Kownacka, Z., Marcinowicz, P., & Szulc, A. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1267647 · Cited by 23
Li, Z., Wu, Q., Peng, P., Wu, M., Liu, S., & Liu, T. (2023) · Psychiatry Research · doi:10.1016/j.psychres.2023.115640 · Cited by 21
Pan, Y., Gorenflo, M. P., Davis, P. B., Kaelber, D. C., Luca, S. M. D., & Xu, R. (2024) · Translational Psychiatry · doi:10.1038/s41398-024-03033-4 · Cited by 23
Aleksandrova, L. R., Wang, Y. T., & Phillips, A. G. (2017) · Chronic Stress · doi:10.1177/2470547017743511 · Cited by 23
Ketamine for Treatment-Resistant Mood Disorders
Park, L. T., Falodun, T. B., & Zarate, C. A. (2019) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.20180030 · Cited by 22
Self-citationKetamine as Potential Treatment for Postpartum Depression: A Narrative Review
Chen-Li, D. C. J., Lui, L. M. W., Rosenblat, J. D., Lipsitz, O., Teopiz, K. M., Ho, R., Vinberg, M., Golts, M., Jawad, M. Y., Lee, Y. L., et al. (2022) · Annals of Clinical Psychiatry · doi:10.12788/acp.0082 · Cited by 20
Phillips, J. L., Geel, A. V., Burhunduli, P., Vasudev, D., Batten, L. A., Norris, S., Talbot, J. D., Ortiz, A., Owoeye, O., & Blier, P. (2022) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyac045 · Cited by 20
Liu, P., Zhang, S., Liang, Y., Gao, Z., Gao, W., & Dong, B. (2022) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s388764 · Cited by 20
Sustained Improvement of Negative Self-Schema After a Single Ketamine Infusion: An Open-Label Study
Hasler, G., Suker, S., Schoretsanitis, G., & Mihov, Y. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00687 · Cited by 19
Tian, Z. R., Dong, C., Zhang, K., Chang, L., & Hashimoto, K. (2018) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyy072 · Cited by 18
Kadriu, B., Subramanian, S., Deng, Z., Henter, I. D., Park, L. T., & Zarate, C. A. (2019) · Oxford University Press eBooks · doi:10.1093/med/9780190929565.003.0013 · Cited by 18
Self-citationJohnston, J. N., Allen, J., Shkolnikov, I., Sánchez-Lafuente, C. L., Reive, B. S., Scheil, K., Liang, S., Christie, B. R., Kalynchuk, L. E., & Caruncho, H. J. (2023) · eNeuro · doi:10.1523/eneuro.0106-23.2023 · Cited by 18
Chang, L., Zhang, K., Pu, Y., Qu, Y., Wang, S., Xiong, Z., Shirayama, Y., & Hashimoto, K. (2019) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-019-01012-1 · Cited by 18
Peng, F., Fan, J., Ge, T., Liu, Q. Q., & Li, B. J. (2020) · Cell Proliferation · doi:10.1111/cpr.12804 · Cited by 19
Vasiliu, O. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.884155 · Cited by 19
Are 24-hour motor activity patterns associated with continued rapid response to ketamine?
Duncan Jr, W. C., Slonena, E. E., Hejazi, N. S., Brutsche, N., Park, L. T., Henter, I. D., Ballard, E. D., & Zarate Jr, C. A. (2018) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s172089 · Cited by 17
Self-citationThe role of NMDARs in the anesthetic and antidepressant effects of ketamine
Zhou, L., & Duan, J. (2023) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14464 · Cited by 17
Kurzweil, L., Danyeli, L. V., Şen, Z. D., Fejtová, A., Walter, M., & Gensberger‐Reigl, S. (2020) · Journal of Chromatography B · doi:10.1016/j.jchromb.2020.122214 · Cited by 17
Dong, C., Tian, Z. R., Fujita, Y., Fujita, A., Hino, N., Iijima, M., & Hashimoto, K. (2021) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2021.173316 · Cited by 17
Li, Q., Wu, H., Fan, S., Liu, D.-X., Jiang, H., Zhang, Q., & Pan, F. (2019) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2019.172742 · Cited by 17
Rapid Antidepressant Activity of Ketamine Beyond NMDA Receptor
Hashimoto, K. (2017) · Springer eBooks · doi:10.1007/978-3-319-49795-2_4 · Cited by 16
Kohtala, S., & Rantamäki, T. (2021) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.13598 · Cited by 16
Xiong, Z., Zhang, K., Ishima, T., Ren, Q., Ma, M., Pu, Y., Chang, L., Chen, J., & Hashimoto, K. (2018) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2018.11.010 · Cited by 16
Repeated, low-dose oral esketamine in patients with treatment-resistant depression: pilot study
Smith-Apeldoorn, S. Y., Veraart, J. K. E., Ruhé, H. G., Rot, M. A. H., Kamphuis, J., de Boer, M. K., & Schoevers, R. A. (2021) · BJPsych Open · doi:10.1192/bjo.2021.1059 · Cited by 17
Castillo, A., Dubois, J., Field, R. M., Fishburn, F. A., Gundran, A., Ho, W. C., Jawhar, S., Kates‐Harbeck, J., Aghajan, Z. M., Miller, N., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-38258-8 · Cited by 16
Regulation of cytochrome P450 gene expression by ketamine: a review
Chen, J., Wei, L., Chen, T.-L., Huang, C., & Chen, R. (2018) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2018.1487397 · Cited by 17
Microglial BDNF modulates arketamine’s antidepressant-like effects through cortico-accumbal pathways
He, L., Wang, X., Luo, S., Jiang, N., Yan, Y., Xie, M., Chen, Y., Yang, C., Yao, W., Hashimoto, K., et al. (2025) · Science Advances · doi:10.1126/sciadv.adv5986 · Cited by 17
Metadata
- Authors
- Kishimoto, T., Chawla, J. M., Hagi, K., Zarate, C. A., Kane, J. M., Bauer, M., & Correll, C. U.
- Affiliations
- Northwell Health (US)
- University Hospital Carl Gustav Carus (DE)
- Corresponding author
- Correll, C. U.
- Venue
- Psychological Medicine
- Publisher
- Cambridge University Press (CUP)
- Published
- 2016-02-12
- Volume
- 46
- Issue
- 7
- Pages
- 1459-1472
- ISSN
- 0033-2917 (ISSN-L)
- 1469-8978
- PMC
- PMC5116384
- OpenAlex
- W2326374493
- Cited by
- 359
- References
- 56
- Citations by year
- 2026: 16 · 2025: 26 · 2024: 26 · 2023: 44 · 2022: 40 · 2021: 56 · 2020: 42 · 2019: 33 · 2018: 39 · 2017: 24 · 2016: 12
- FWCI
- 4.12
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Psychological Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- American Foundation for Suicide Prevention
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Teva Pharmaceutical Industries
- Stanley Medical Research Institute
- Sunovion
- National Alliance for Research on Schizophrenia and Depression
- European Commission
- Deutsche Forschungsgemeinschaft
- Bundesministerium für Bildung und Forschung
- Novo Nordisk
- Astellas Pharma
- Shionogi
- Servier
- H. Lundbeck A/S
- National Institutes of Health
- Genentech
- National Institute of Mental Health (P30MH090590, ZIAMH002857)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Keywords
- ketamine, NMDA receptor antagonists, major depressive disorder, bipolar depression, treatment-resistant depression, antidepressant efficacy, remission, discontinuation, adverse effects, class effect, placebo response, treatment cost-effectiveness
- MeSH terms
- Antidepressive Agents, Bipolar Disorder, Major Depressive Disorder, Humans, Ketamine, Receptors, N-Methyl-D-Aspartate, Outcome Assessment, Health Care, Excitatory Amino Acid Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
